pharmaphorum14d
GSK's Nucala gains US use in rare autoimmune disease
GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...
techworm.net18d
10 Best Icon Packs for Windows 10 in 2025 [ Free Download ]
Unlike older Windows operating systems, Windows 10 has a lot of wonderful premium features. One of these is the well-designed icon for each of the system’s files. However, at some time, we all want to ...
Bleacher Report21d
Lakers Rumors: LA Has 'a Real Desire to See' 2nd Unit Before Making Another Trade
The Los Angeles Lakers are still evaluating their internal options as they weigh up any additional trades before the Feb. 6 deadline, according to the Los Angeles Times' Dan Woike. "Instead of ...
Daily22d
GSK Nucala approved in China for treatment of adults with chronic rhinosinusitis with nasal polyps
London: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on therapy ...
Pharmabiz22d
GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps
GSK plc announced that the China National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on therapy with ...
Yahoo Finance22d
GSK’s Nucala Gains Approval in China for CRSwNP
GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 ...
ENDPOINTS NEWS23d
GSK’s Nu­cala bags an­oth­er Chi­na ap­proval, but biggest test yet to come
GSK’s block­buster res­pi­ra­to­ry drug Nu­cala has se­cured a Chi­na la­bel ex­pan­sion for cer­tain pa­tients with in­flamed si­nus­es. But a more im­por­tant chal­lenge on ...
ENDPOINTS NEWS23d
Af­ter Ca­griSe­ma, eyes are on Lil­ly’s oral GLP-1 as next key obe­si­ty play
With the dis­ap­point­ment of No­vo Nordisk’s in­ject­ed Ca­griSe­ma in obe­si­ty at the end of 2024, ...
Nasdaq23d
GSK’s Nucala Gains Approval in China for CRSwNP
Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 million people in the country. This approval ...
Business Insider23d
GSK’s Nucala approved in China as add-on therapy for adults with CRSwNP
GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that targets interleukin-5, as an add-on therapy with intranasal ...
The Pharma Letter23d
GSK’s Nucala wins wider approval in China
China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK pharma major GSK (LSE: GSK) that targets interleukin-5 (IL-5). The new ...